中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

索拉菲尼在肝癌治疗中的不良反应

杨曼 祁兴顺 韩国宏

引用本文:
Citation:

索拉菲尼在肝癌治疗中的不良反应

DOI: 10.3969/j.issn.1001-5256.2014.03.021
详细信息
  • 中图分类号: R735.7

Sorafenib-related adverse events in treatment of hepatocellular carcinoma

  • 摘要:

    索拉菲尼可以显著改善晚期肝癌患者的预后,它主要通过拮抗血管内皮生长因子受体和血小板衍生生长因子受体抗血管源性靶点及通过抑制Raf/MEK/ERK信号传导通路直接抑制肿瘤生长而发挥抗肿瘤作用。然而,频发的索拉菲尼相关的不良反应将影响患者的生活质量。文中简述了小分子靶向药物索拉菲尼治疗肝癌的药理机制,归纳总结了索拉菲尼相关常见不良反应的发生率、特点、预防和治疗措施,并指出索拉菲尼相关的不良反应和抗肿瘤疗效相关,认为临床医生应该充分权衡索拉菲尼在治疗肝癌患者中不良反应的利与弊。

     

  • [1]CHEN JG.Trends in the incidence of liver cancer and its primary prevention in China[J].J Clin Hepatol, 2012, 28 (4) :256-260. (in Chinese) 陈建国.中国肝癌发病趋势和一级预防[J].临床肝胆病杂志, 2012, 28 (4) :256-260.
    [2]TANG ZY.21st century:challenges facing the clinical research of liver cancer[J].J Clin Hepatol, 2012, 28 (4) :241-242. (in Chinese) 汤钊猷.21世纪肝癌临床面临的挑战[J].临床肝胆病杂志, 2012, 28 (4) :241-242.
    [3] ELLIS LM, HICKLIN DJ.VEGF-targeted therapy:mechanisms of anti-tumour activity[J].Nat Rev Cancer, 2008, 8 (8) :579-591.
    [4] LLOVET JM, RICCI S, MAZZAFERRO V, et al.Sorafenib in advanced hepatocellular carcinoma[J].N Engl J Med, 2008, 359 (4) :378-390.
    [5]CHENG AL, KANG YK, CHEN Z, et al.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma:a phase III randomised, double-blind, placebo-controlled trial[J].Lancet Oncol, 2009, 10 (1) :25-34.
    [6]ANDERSON R, JATOI A, ROBERT C, et al.Search for evidence-based approaches for the prevention and palliation of hand–foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs) [J].Oncologist, 2009, 14 (3) :291-302.
    [7]ROBERT C, SORIA JC, SPATZ A, et al.Cutaneous side-effects of kinase inhibitors and blocking antibodies[J].Lancet Oncol, 2005, 6 (7) :491-500.
    [8]AUTIER J, ESCUDIER B, WECHSLER J, et al.Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor[J].Arch Dermatol, 2008, 144 (7) :886-892.
    [9]SCHUTZ F, JE Y, RICHARDS C, et al.Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors[J].J Clin Oncol, 2012, 30 (8) :871-877.
    [10]SIVENDRAN S, LIU Z, PORTAS LJ JR, et al.Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors:A meta-analysis[J].Cancer Treatment Reviews, 2012, 38 (7) :919-925.
    [11]JE Y, SCHUTZ F, CHOUEIRI TK.Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib:a systematic review and meta-analysis of clinical trials[J].Lancet Oncol, 2009, 10 (10) :967-974.
    [12]HERNON M, HOYERT DL, MURPHY SL, et al.Deaths:Final data for 2006[J].Natl Vital Stat Rep, 2009, 57 (14) :1-134.
    [13]National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0[S/OL].[2006-08-09].http://ctep.cancer.gov/.
    [14]IAVARONE M, CABIBBO G, PISCAGLIA F, et al.Field-practice study of sorafenib therapy for hepatocellular carcinoma:A prospective multicenter study in Italy[J].Hepatology, 2011, 54 (6) :2055-2063.
    [15]CHU D, LACOUTURE ME, FILLOS T, et al.Risk of hand-foot skin reaction with sorafenib:a systematic review and meta-analysis[J].Acta Oncol, 2008, 47 (2) :176-186.
    [16]ROBERT C, MATEUS C, SPATZ A, et al.Dermatologic symptoms associated with the multikinase inhibitor sorafenib[J].J Am Acad Dermatol, 2009, 60 (2) :299-305.
    [17]AZAD NS, Aragon-Chin JB, Dahut WL, et al.Hand-Foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy[J].Clin Cancer Res, 2009, 15 (4) :1411-1416.
    [18]LEE JH, CHUNG YH, KIM JA, et al.Genetic predisposition of Hand-Foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma[J].Cancer, 2012, 119 (1) :136-142.
    [19]MIR O, CORIAT R, BOUDOU-ROUQUETTE P, et al.Sorafenib-induced diarrhea and hypophosphatemia:mechanisms and therapeutic implications[J].Ann Oncol, 2012, 23 (1) :280-281.
    [20]ZHAO Y, YANG M, QI X, et al.Drug-related adverse events may predict efficacy in sorafenib therapy for hepatocellular carcinoma[J].Hepatology, 2012, 56 (2) :790-791.
    [21]SONG T, ZHANG W, WU Q, et al.A single center experience of sorafenib in advanced hepatocellular carcinoma patients:evaluation of prognostic factors[J].Eur J Gastroenterol Hepatol, 2011, 23 (12) :1233-1238.
    [22] LUO XN, LU LG, SHAO PJ, et al.Relationship between sorafenibassociated hand-food skin reaction and efficacy in treatment of advanced hepatocellular carcinoma[J].Natl Med J China, 2012, 92 (13) :889-893. (in Chinese) 罗小宁, 陆骊工, 邵培坚, 等.索拉菲尼治疗中晚期肝癌相关的手足皮肤反应与疗效的关系[J].中华医学杂志, 2012, 92 (13) :889-893.
    [23] VINCENZI B, SANTINI D, RUSSO A, et al.Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib[J].Oncologist, 2010, 15 (1) :85-92.
    [24]OTSUKA T, EGUCHI Y, KAWAZOE S, et al.Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib[J].Hepatol Res, 2012, 42 (9) :879-886.
    [25]ESTFAN B, BYRNE M, KIM R.Sorafenib in advanced hepatocellular carcinoma:hypertension as a potential surrogate marker for efficacy[J].Am J Clin Oncol, 2013, 36 (4) :319-324.
    [26]BETTINGER D, SCHULTHEISS M, KNPPEL E, et al.Diarrhea predicts a positive response to sorafenib in patients with advanced hepatocellular carcinoma[J].Hepatology, 2012, 56 (2) :789-790.
    [27]KAMBA T, MCDONALD DM.Mechanisms of adverse effects of antiVEGF therapy for cancer[J].Bri J Cancer, 2007, 96 (12) :1788-1795.
  • 加载中
计量
  • 文章访问数:  4095
  • HTML全文浏览量:  12
  • PDF下载量:  767
  • 被引次数: 0
出版历程
  • 出版日期:  2014-03-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回